Not FDA-approved6,9Evidence: Smaller human trialsEyes

Thymosin beta-46

Key takeaway

Thymosin beta-4 is a naturally occurring human peptide recorded in FDA’s substance registry. TB-500, a separate profile, is a short synthetic fragment of it.6 It has been tested as an eye treatment in small randomized trials: in dry eye, its main goals were not met, and in a Phase 3 trial of 18 people with a nerve-related corneal disease, complete healing was more common but not significantly so.7,8 No FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page lists only the TB-500 fragment, and thymosin beta-4 itself is not among the six peptides in HHS’s October 2026 draft policy.6,9,11

Thymosin beta-4 at a glance

What it isHuman thymosin beta-4, also recorded as TMSB4 and TB4X in FDA’s substance registry.6
FDA statusNo FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page lists a thymosin beta-4 fragment, TB-500, among withdrawn nominations, but not thymosin beta-4 itself.6,9
Human evidenceSmall randomized, placebo-controlled eye trials: one in 72 people with dry eye and a Phase 3 trial in 18 people with neurotrophic keratopathy.7,8
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is thymosin beta-4?

Thymosin beta-4 is a human peptide that FDA’s substance registry records under names including human thymosin beta-4, TMSB4 and TB4X.6

TB-500, which FDA’s safety-risk page describes as a thymosin beta-4 fragment (LKKTETQ), is a different, much shorter substance with its own profile on this site.9

How is thymosin beta-4 thought to work?

Trial authors describe it as a regenerative peptide and studied it to promote healing of the surface of the eye.8

The sources reviewed here do not establish its mechanism in people.6,7

What do human studies show?

In a 2015 Phase 2 trial, 72 people with moderate to severe dry eye were randomized to thymosin beta-4 or placebo for 28 days. Neither main outcome, eye discomfort or staining of the lower cornea, differed significantly, though some secondary measures improved.7

In a 2022 Phase 3 trial in 18 people with neurotrophic keratopathy, a nerve-related corneal disease, the defect healed completely by four weeks in 6 of 10 given thymosin beta-4 and 1 of 8 given placebo, a difference the authors reported as a trend rather than significant.8

ClinicalTrials.gov lists two further Phase 3 dry eye trials (NCT02974907 and NCT03937882) and a Phase 3 neurotrophic keratopathy trial (NCT05555589) as completed in their 2026 registry records, and earlier completed Phase 2 trials in pressure ulcers (NCT00382174) and venous stasis ulcers (NCT00832091). The registry records cited here do not report their findings.1,2,3,4,5

What the evidence base contains

  • Controlled human trial A randomized, double-masked, placebo-controlled Phase 2 trial in 72 people with moderate to severe dry eye (2015).7
  • Controlled human trial A randomized, double-masked, placebo-controlled Phase 3 trial in 18 people with neurotrophic keratopathy and a persistent corneal defect (2022).8

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is thymosin beta-4 FDA-approved?

None of the sources reviewed here reports an approval of thymosin beta-4 by FDA.6,9

FDA’s compounding safety-risk page, current as of April 22, 2026, lists “thymosin beta-4, fragment (LKKTETQ), also known as TB-500” among withdrawn nominations with possible safety risks. It does not list full-length thymosin beta-4.9

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Thymosin beta-4 is not among them; TB-500 is a fragment of it.10,11

Timeline

  1. A Phase 2 dry eye trial of thymosin beta-4 in 72 people is published.7
  2. A Phase 3 trial of thymosin beta-4 in 18 people with neurotrophic keratopathy is published.8
  3. FDA’s compounding safety-risk page, as last updated, lists the TB-500 fragment but not thymosin beta-4 itself.9

What is still unknown?

Whether it works for any eye disease: the published trials were small, and their main outcomes were not met or did not reach significance.7,8

Whether findings from eye trials say anything about other uses, which these trials did not test.7,8

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Thymosin beta-4: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Thymosin beta-4 are a bounded selection, not every registration or paper about Thymosin beta-4. For the years before Thymosin beta-4 was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Thymosin beta-4 as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Thymosin beta-4 in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

No FDA approval reported. Small randomized eye trials found that main outcomes were not met or did not reach significance. Thymosin beta-4 is not among the six peptides in HHS’s October 2026 draft policy, which lists the TB-500 fragment.↗↗↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Thymosin beta-4?

No FDA approval reported. Small randomized eye trials found that main outcomes were not met or did not reach significance. Thymosin beta-4 is not among the six peptides in HHS’s October 2026 draft policy, which lists the TB-500 fragment.↗↗↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
2
Source years
5
Drugs@FDA applications
0

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Collection changes

What did PeptideScanner add most recently?

  1. Literature metadata · added November 16, 2026

    Role of Thymosin Beta 4 in the diagnosis of Nonalcoholic Fatty Liver and its relation to Metabolic Syndrome in Egyptian patients.↗Source date November 9, 2026
  2. Clinical trials · added November 16, 2026

    ClinicalTrials.gov record NCT05555589↗Source date November 5, 2026
  3. Literature metadata · added November 16, 2026

    The preliminary study of exosomes derived from thymosin beta 4-treated adipose-derived stem cells in fat grafting.↗Source date October 30, 2026

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Thymosin beta-4?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

32Selected dated records
38Connected citations
5Populated source years2010–2026
2/4Record lanes present

Registered human studies

Trial composition

7 of 7 selected trial records include at least one phase value; 7 of 7 include a status value in the retained structured contract.

PhasesPhase 2 4Phase 3 4
Status at observationCompleted 7

PubMed bibliography

Publication composition

25 of 25 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 25Research Support, Non-U.S. Gov't 13Review 7Research Support, N.I.H., Extramural 2Personal Narrative 1Research Support, U.S. Gov't, Non-P.H.S. 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
32

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 32 dated records

Research hub

Explore the Thymosin beta-4 evidence record

Open all 32 records →
32Dated records
2Evidence types
32Cited public sources
5Source years

Change ledger

Recently changed for Thymosin beta-4

Open all 32 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT00382174

PeptideScanner retained ClinicalTrials.gov record NCT00382174 at 2026-11-16T01:44:56.605Z. Its registry update date was 2010-02-01, and PeptideScanner's reviewed identity mapping was thymosin-beta-4.

PeptideScanner change date
November 16, 2026
Cited source date
February 1, 2010
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00832091

PeptideScanner retained ClinicalTrials.gov record NCT00832091 at 2026-11-16T01:44:56.605Z. Its registry update date was 2010-03-30, and PeptideScanner's reviewed identity mapping was thymosin-beta-4.

PeptideScanner change date
November 16, 2026
Cited source date
March 30, 2010
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01387347

PeptideScanner retained ClinicalTrials.gov record NCT01387347 at 2026-11-16T01:44:56.605Z. Its registry update date was 2015-07-10, and PeptideScanner's reviewed identity mapping was thymosin-beta-4.

PeptideScanner change date
November 16, 2026
Cited source date
July 10, 2015
Evidence lane
Clinical trials

Official-source collections

Source records for Thymosin beta-4

Open the full research atlas →
PubMed25

25 with attributed title, venue, publication-date, and type metadata.

  1. Thymosin beta 4: An emerging therapeutic candidate for kidney diseases.Peptides · 2026 01 20
  2. Thymosin beta 4 as an Alzheimer disease intervention target identified using human brain organoids.Stem cell reports · 2025 08 14
  3. Thymosin beta-4 denotes new directions towards developing prosperous anti-aging regenerative therapies.International immunopharmacology · 2023 01 27
Explore all selected literature →
ClinicalTrials.gov7

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT05555589Registry update November 5, 2026 · completed at observation
  2. NCT02974907Registry update October 21, 2026 · completed at observation
  3. NCT03937882Registry update August 28, 2026 · completed at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span February 1, 2010 to November 9, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration6,9
  • U.S. Department of Health and Human Services10
Dated updates connected to this profile · 32

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Role of Thymosin Beta 4 in the diagnosis of Nonalcoholic Fatty Liver and its relation to Metabolic Syndrome in Egyptian patients.↗

    PubMed lists PMID 35436057 in The Egyptian journal of immunology as Journal Article, with publication-date metadata of 2022-04 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-beta-4. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT05555589↗

    PeptideScanner retained ClinicalTrials.gov record NCT05555589 at 2026-11-16T01:44:56.605Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was thymosin-beta-4.↗

  3. Literature metadata

    The preliminary study of exosomes derived from thymosin beta 4-treated adipose-derived stem cells in fat grafting.↗

    PubMed lists PMID 36445571 in Genes & genomics as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-11-29 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-beta-4. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT02974907↗

    PeptideScanner retained ClinicalTrials.gov record NCT02974907 at 2026-11-16T01:44:56.605Z. Its registry update date was 2026-10-21, and PeptideScanner's reviewed identity mapping was thymosin-beta-4.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT03937882↗

    PeptideScanner retained ClinicalTrials.gov record NCT03937882 at 2026-11-16T01:44:56.605Z. Its registry update date was 2026-08-28, and PeptideScanner's reviewed identity mapping was thymosin-beta-4.↗

  6. Literature metadata

    Thymosin beta 4: An emerging therapeutic candidate for kidney diseases.↗

    PubMed lists PMID 41570941 in Peptides as Journal Article, Review, with publication-date metadata of 2026-01-20 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-beta-4. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Thymosin beta 4 as an Alzheimer disease intervention target identified using human brain organoids.↗

    PubMed lists PMID 40816274 in Stem cell reports as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-08-14 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-beta-4. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Thymosin beta 4 interactions.↗

    PubMed lists PMID 12852258 in Vitamins and hormones as Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Review, with publication-date metadata of 2003 (year precision). PeptideScanner associated the retained record with the identity slug thymosin-beta-4. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Literature metadata

    Thymosin beta-4 and the eye: I can see clearly now the pain is gone.↗

    PubMed lists PMID 17495249 in Annals of the New York Academy of Sciences as Journal Article, Review, with publication-date metadata of 2007-05-10 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-beta-4. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Literature metadata

    Thymosin beta 4 is dispensable for murine cardiac development and function.↗

    PubMed lists PMID 22158707 in Circulation research as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2011-12-08 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-beta-4. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Literature metadata

    Multiple functional involvement of thymosin beta-4 in tooth germ development.↗

    PubMed lists PMID 23052839 in Histochemistry and cell biology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012-10-06 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-beta-4. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Literature metadata

    Production and characterization of highly purified recombinant thymosin beta 4 in Escherichia coli.↗

    PubMed lists PMID 23711379 in Protein expression and purification as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-05-24 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-beta-4. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    ClinicalTrials.gov record NCT02974907 · retained source version 2026-10-21:59d27b0ae4adbcd8f812122dcc9a82866c0f1fdbfd494696a0d39d98746205ec ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  2. 2
    ClinicalTrials.gov record NCT03937882 · retained source version 2026-08-28:3dfc2e0bb1bf0e61f3aac55a4206c16633cb979290ddb57d04f4925082b71139 ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  3. 3
    ClinicalTrials.gov record NCT05555589 · retained source version 2026-11-05:e825071554db7d2d13c4137e49cc1e7ca4c82e221422addc412bad3045733106 ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  4. 4
    ClinicalTrials.gov record NCT00382174 · retained source version 2010-02-01:c721e9358d9c03c06fb3e18d214503e2148f80af5aa10620fe1221b2d9837097 ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  5. 5
    ClinicalTrials.gov record NCT00832091 · retained source version 2010-03-30:45216971d18f0901f3ca739bfd16411400de886073bdcc94882275ad2850c1d2 ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  6. 6
    Thymosin beta-4 substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  7. 7
    Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model (2015) · PMID 26056426 ↗

    Clinical Ophthalmology · Official source · Source checked November 15, 2026

  8. 8
    RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial (2022) · PMID 36613994 ↗

    International Journal of Molecular Sciences · Official source · Source checked November 15, 2026

  9. 9
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  10. 10
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  11. 11
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026